APRE - Aprea Therapeutics Inc Stock Price, Fair Value and News

$3.02+0.04 (+1.34%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

APRE Price Action

Last 7 days

-8.5%

Last 30 days

-7.1%

Last 90 days

-14.5%

Trailing 12 Months

-13.3%

APRE RSI Chart

APRE Valuation

Market Cap

16.4M

Price/Earnings (Trailing)

-1.22

Price/Sales (Trailing)

36.72

Price/Free Cashflow

-1.19

APRE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

APRE Fundamentals

APRE Revenue

Revenue (TTM)

583.2K

Rev. Growth (Yr)

11%

Rev. Growth (Qtr)

-36.85%

APRE Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-18.08%

Earnings Growth (Qtr)

-9.04%

APRE Profitability

Return on Equity

-61.54%

Return on Assets

-50.22%

Free Cashflow Yield

-84.13%

APRE Investor Care

Shares Dilution (1Y)

45.45%

Diluted EPS (TTM)

-2.79

APRE Alerts

2 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	583.2K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

CEO	Dr. Oren Gilad Ph.D.
WEBSITE	aprea.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	9

Aprea Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aprea Therapeutics Inc? What does APRE stand for in stocks?

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aprea Therapeutics Inc (APRE)?

As of Tue Nov 19 2024, market cap of Aprea Therapeutics Inc is 16.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers.

Is Aprea Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APRE is over valued or under valued. Whether Aprea Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aprea Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APRE.

What is Aprea Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 19 2024, APRE's PE ratio (Price to Earnings) is -1.22 and Price to Sales (PS) ratio is 36.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.